Search Results

Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides information to its stockholders regarding short selling of Scilex common stocks traded on the Nasdaq Capital Market.

Scilex Holding Company announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and highly respected distributor with over 10 years of sales excellence, Endeavor Distribution LLC.

Virpax ® Pharmaceuticals, Inc. today announced that it has entered into a term sheet to settle the litigation with the Company and Sorrento Therapeutics, Inc. (Sorrento) and Scilex Pharmaceuticals, Inc. (Scilex and Sorento, collectively, the “Plaintiffs”).

Scilex Holding Company provided certain preliminary unaudited financial results for the month ended June 30, 2024 and quarter ended June 30, 2024.

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”) today announced the publication of results of the pivotal registration trial of SP-102 (SEMDEXA™) in PAIN, the official journal of the International Association for the Study of Pain, which features original research on the nature, mechanisms and treatment of pain.

Scilex Holding Company, an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that many national pharmacy chains and independent pharmacy stores have begun stocking GLOPERBA®.

Scilex Holding Company announced that it has the FDA approval of commercial manufacturing of Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. and will launch in June 2024.

Scilex Holding Company announced it will be presenting a poster on ELYXYB® at the 66th Annual Scientific Meeting of the American Headache Society to be held in San Diego, CA on June 13-16, 2024.